Category: MS Drug Therapies

Talking Biosimilars – Unlocking Patient access through coordinated action

Stuart Schlossman

Beyond One Drug: What the Tolebrutinib Decision Teaches Us About Progressive MS Trials.

Stuart Schlossman

Genentech’s Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

Stuart Schlossman

Ocrevus and Tysabri appear to work equally well to control relapsing MS

Stuart Schlossman

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Stuart Schlossman

Predictors of initiating high-efficacy vs. platform therapies as first-line disease-modifying treatment in multiple sclerosis

Stuart Schlossman

REFRAMING MS

Stuart Schlossman

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

Stuart Schlossman

Do you Know about the 2-TIMES-A-YEAR* OCREVUS and its AVAILABILITY for treating RMS and PPMS TWO different ways?

Stuart Schlossman

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Category: MS Drug Therapies

Talking Biosimilars – Unlocking Patient access through coordinated action

Stuart Schlossman

Beyond One Drug: What the Tolebrutinib Decision Teaches Us About Progressive MS Trials.

Stuart Schlossman

Genentech’s Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

Stuart Schlossman

Ocrevus and Tysabri appear to work equally well to control relapsing MS

Stuart Schlossman

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Stuart Schlossman

Predictors of initiating high-efficacy vs. platform therapies as first-line disease-modifying treatment in multiple sclerosis

Stuart Schlossman

REFRAMING MS

Stuart Schlossman

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

Stuart Schlossman

Do you Know about the 2-TIMES-A-YEAR* OCREVUS and its AVAILABILITY for treating RMS and PPMS TWO different ways?

Stuart Schlossman

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Stuart Schlossman

Latest Blog Posts

Category: MS Drug Therapies

Talking Biosimilars – Unlocking Patient access through coordinated action

Stuart Schlossman

Beyond One Drug: What the Tolebrutinib Decision Teaches Us About Progressive MS Trials.

Stuart Schlossman

Genentech’s Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

Stuart Schlossman

Ocrevus and Tysabri appear to work equally well to control relapsing MS

Stuart Schlossman

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Stuart Schlossman

Predictors of initiating high-efficacy vs. platform therapies as first-line disease-modifying treatment in multiple sclerosis

Stuart Schlossman

REFRAMING MS

Stuart Schlossman

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

Stuart Schlossman

Do you Know about the 2-TIMES-A-YEAR* OCREVUS and its AVAILABILITY for treating RMS and PPMS TWO different ways?

Stuart Schlossman

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Stuart Schlossman

Latest Blog Posts

Join The MS Community